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A b s t r a c t
Background: New generation cardiac troponin assays have sufficient precision to detect and quantify plasma troponin con-
centrations below the lower threshold of detection of the currently employed troponin tests. However, diagnostic perfor-
mance of the newer generation assays in daily clinical practice is not well established.
Aim: To evaluate the diagnostic performance of a sensitive assay as compared to a standard assay in a single reading at
admission in the diagnosis of acute myocardial infarction (AMI) in patients presenting to the Emergency Department with
chest pain.
Methods: The study comprised 187 consecutive patients admitted to the Institute of Cardiology in Warsaw in June and July
2010 with chest pain in whom the attending physician ordered troponin assay to rule AMI in or out. In all of these patients,
in addition to the standard Dimension Flex Troponin I (Siemens Healthcare Diagnostics, Inc.) the sensitive Architect Stat
Troponin I (Abbott Diagnostics) test was assayed. The triage of patients as well as all diagnostic and treatment decisions were
left to the discretion of the attending physician who was blinded to the sensitive troponin test readings. The final diagnosis
was adjudicated by a team of two cardiologists on the basis of all the available medical records except for sensitive troponin
test results.
Results: Mean age of the study cohort (n = 187) was 64.3 ± 13.9 years and 119 (63.6%) were males. The final diagnosis of
AMI was adjudicated in 84 (44.9%) patients (mean age 67.5 ± 12.9 years; 119 [63.6%] males). Receiver operating character-
istic (ROC) analysis showed greater area under the curve (AUC) for the sensitive cardiac troponin assay compared to the
standard assay (AUC = 0.916, 95% CI = 0.866–0.951 vs AUC = 0.863, 95% CI = 0.806–0.909, respectively; p = 0.02) in
a single reading at admission. Sensitive assay was characterised by higher sensitivity (87%), specificity (88%), positive (86%)
and negative (89%) predictive values in the detection of AMI compared to the standard troponin test (82%, 81%, 78%, and
85% respectively).
Conclusions: The newer generation sensitive cardiac troponin assay presented superior diagnostic accuracy in the diagnosis
of AMI compared to the standard troponin test in a single reading at admission with improved sensitivity and specificity. The
sensitive troponin assay has the potential to improve early detection and/or exclusion of AMI.
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INTRODUCTION
Acute myocardial infarction (AMI) remains one of the leading
causes of mortality and morbidity in industrialised countries
[1–3]. Treatment options are now in place that are capable of
limiting, or even preventing, early and late adverse consequen-
ces of AMI [4, 5]. However, early and accurate diagnosis of
AMI enables timely and appropriate implementation of these
therapies, and thus is key to their effectiveness. In the very
early stages of ST-elevation myocardial infarction (STEMI) cli-
nical signs and symptoms coupled with ECG changes are often
sufficient to make appropriate diagnosis and initiate treatment
without unnecessary delay caused by waiting for elevation of
troponin levels [4, 6, 7]. Nevertheless, early and accurate dia-
gnosis of non-ST elevation myocardial infarction (NSTEMI)
remains a daily clinical challenge. On the other hand, fast,
accurate, and reliable exclusion of the ongoing myocardial
necrosis in the environment of the Emergency Department
(ED) is crucial to ensure appropriate triage of patients, pre-
vent EDs’ overcrowding, and reduce the overall cost burden
of healthcare [8].
Cardiac troponins are structural proteins specific to car-
diomyocytes and as such play a central role in the diagnostic
process of AMI [9, 10]. The significance of troponin blood
concentrations has recently been corroborated by The Joint
ESC/ACCF/AHA/WHF Task Force for the Universal Defini-
tion of Myocardial Infarction. The Task Force states that in
order to diagnose AMI a rising and/or falling pattern of tropo-
nin blood concentration with at least one value above the
99th percentile of the upper reference limit of the healthy re-
ference population needs to be detected [11]. Elevated pla-
sma cardiac troponin levels should be interpreted together
with the entire clinical context and AMI may be considered if
angina, ischaemic ECG abnormalities, or newly present my-
ocardial dysfunction are detected.
A substantial time gap exists between the onset of MI
and the rise of cardiac troponin blood levels detectable by
the current troponin assays with sufficient accuracy. This de-
lay often requires subsequent troponin tests at six-hourly in-
tervals to confirm or exclude the diagnosis of AMI [11]. Re-
cent developments in immunoassay technology have allo-
wed for the construction of new generation troponin assays
capable of detecting much lower concentrations of cardiac
troponins in the blood with high precision [10, 12]. These
assays may allow for the detection of raised troponin with
greater accuracy and earlier in the process of the ongoing
myocardial necrosis. However, diagnostic performance of
these new generation assays in daily clinical practice is not
well established. Therefore, the aim of the current analysis
was to evaluate the diagnostic performance of the sensitive
troponin assay in comparison with the standard troponin as-




The study comprised consecutive patients admitted to the
Institute of Cardiology with chest pain in whom the attending
physician suspected acute coronary syndrome (ACS) and or-
dered troponin assay. The total number of 187 patients were
enrolled from June to July of 2010.
Study methods
The study was observational in nature, therefore the triage of
patients as well as all the diagnostic and treatment decisions
were left to the discretion of the attending physician who re-
mained blinded to the sensitive troponin assay readings.
Blood samples for troponin assays were collected within
24 hours from the onset or peak of symptoms. The routine
troponin test was Dimension Flex Troponin I (Siemens Health-
care Diagnostics, Inc.) and this assay was used in the current
analysis as the reference. Additionally, in all of the study pa-
tients, sensitive Architect Troponin I (Abbott Diagnostics) was
assayed as part of its validation at the hospital’s laboratory.
Blood samples for the determination of investigational car-
diac troponin assay were stored frozen at –20°C until they
were assayed in a blinded fashion. The remaining laboratory
tests were performed as ordered by the attending physician.
All laboratory tests were performed in the Diagnostyka Labo-
ratory sp. z o.o. SK in the Institute of Cardiology.
The final diagnosis was adjudicated by a team of two
experienced cardiologists on the basis of all the available
medical records with the exception of sensitive troponin test
results. If there was disagreement between the two cardiolo-
gists, the opinion of a third, independent, specialist was so-
ught. The final diagnosis fell into one of three predefined ca-
tegories: (1) AMI (STEMI or NSTEMI); (2) unstable angina (UA);
or (3) non-acute coronary syndrome (non-ACS). The diagno-
sis of AMI was established according to the criteria proposed
by The Joint ESC/ACCF/AHA/WHF Task Force for the Uni-
versal Definition of Myocardial Infarction, i.e. detection of
rise and/or fall of cardiac biomarkers of necrosis (troponin)
with at least one value above the 99th percentile of the upper
reference limit (URL) together with myocardial ischaemia as
evidenced by typical angina, ischaemic ECG changes, ima-
ging evidence of new loss of viable myocardium or new re-
gional wall motion abnormalities [11]. Unstable angina was
diagnosed in patients in whom coronary artery disease was
established based on previously or currently performed inva-
sive or noninvasive coronary angiography or who had docu-
mented exertion ischaemia on exercise test, and who had
typical rest angina or recent deterioration of exertion angina
without elevation of blood troponin levels. Patients in the third
category had chest pain with apparent cardiac cause other
than ACS (e.g. perimyocarditis, tachyarrythmias) or any other
non-cardiac cause (e.g. acute pulmonary embolism) or had
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chest pain of unclear origin excluding ACS. A subgroup of
patients with chest pain of apparent origin other then ACS
and troponin elevation above the 99th percentile was pre-
specified.
The adjudication process was based on the Dimension
Flex Troponin I assay (Siemens Healthcare Diagnostics, Inc.,
Newark, DE, USA) with the lower limit of detection (LOD)
equal to 0.04 ng/mL, 99th percentile of URL at 0.07 ng/mL
with imprecision at this concentration equal to 15–22% co-
efficient of variation (CV), and imprecision of 10% at the con-
centration of 0.14 ng/mL, as specified by the manufacturer.
The sensitive troponin assay tested in the current analysis was
Architect Stat Troponin I assay performed with the use of the
Architect system (Abbott Diagnostics, Abbott Park, IL, USA),
with LOD equal to 0.01 ng/mL, 99th percentile of URL at
0.028 ng/mL with imprecision at this concentration equal to
15% CV, and a CV of less than 10% at 0.032 ng/mL, as speci-
fied by the manufacturer.
The study was approved by the local ethics committee
and conformed to the principles of the Declaration of Helsin-
ki. The sensitive troponin assay was provided by the manu-
facturer free of charge. The study design, data gathering and
analysis, as well as drafting of the manuscript and its subsequ-
ent submission for publication have been carried out by the
authors independently of and without any interference on
the part of the manufacturer.
Statistical analysis
The data analysis was performed using SPSS statistical analy-
sis software (SPSS Inc., Chicago, IL, USA) and Medcalc stati-
stical software (Medcalc, Belgium). Continuous variables were
presented as mean ± SD and compared using Mann-Whit-
ney U test. Categorical variables were summarised as num-
bers and percentages and compared using c2 or Fishers’ exact
test as appropriate. Receiver operating characteristic (ROC)
curves were constructed to obtain areas under the curves
(AUC), sensitivity, specificity, as well as positive and negative
predictive values (NPV and PPV, respectively) of cardiac tropo-
nin levels determined at presentation in the diagnosis of AMI.
The comparison of areas under the ROC curves (AUC) was per-
formed as recommended by DeLong et al. [13]. Two-tailed
hypotheses testing was used in all analyses and a p-value of
less than 0.05 was considered statistically significant.
RESULTS
Baseline data
The study cohort comprised 187 patients of whom 119
(63.6%) were male and the mean age was 64.3 ± 13.9 years.
The AMI was the adjudicated diagnosis in 84 (44.9%) patients.
A total of 43 (23.0%) patients had STEMI and 41 (21.9%) had
NSTEMI. In the remaining 103 (55.1%) cases: UA was the
final adjudicated diagnosis in 11 (5.9%) and non-ACS in 92
(49.2%) patients. Demographic and clinical characteristics of
the study group are presented in Table 1.
Troponin levels
Patients with AMI had higher troponin concentrations at ad-
mission compared to patients in whom AMI was excluded
(11.723 ± 36.263 vs 0.220 ± 1.177 ng/mL, respectively for
the sensitive troponin assay, and 11.32 ± 32.80 vs 0.29 ±
± 1.27 ng/mL, respectively for the standard troponin assay;
p < 0.01 for both). Patients with UA and non-ACS had simi-
lar troponin levels as determined by sensitive (0.007 ± 0.004
vs 0.245 ± 1.244 ng/mL; p = NS) or standard (0.04 ± 0.03
Table 1. Selected demographic and clinical characteristics of the study group
Variable Overall study group Patients with AMI Patients without AMI P
(n = 187) (n = 84) (n = 103 )
Male gender 119 (63.6%) 55 (65.5%) 64 (62.1%) NS
Age 64.3 ± 13.9 67.5 ± 12.9 61.7 ± 14.4 < 0.01
Age ≥ 65 years 94 (50.3%) 46 (54.8%) 48 (46.6%) NS
Hypertension 114 (61.0%) 58 (69%) 56 (54.4%) 0.05
Hyperlipidaemia 68 (36.4%) 49 (58%) 19 (18.4%) < 0.001
Diabetes mellitus 27 (14.4%) 17 (20.2%) 10 (9.7%) 0.06
Smoking history 26 (13.9%) 18 (21.4%) 8 (7.8%) 0.01
Family history 7 (3.7%) 5 (6.0%) 2 (1.9%) NS
Previous MI 33 (17.6%) 14 (16.7%) 19 (18.4%) NS
Previous PTCA 30 (16.0%) 11 (13.1%) 19 (18.4%) NS
Previous CABG 15 (8.0%) 6 (7.1%) 9 (8.7%) NS
History of stroke 3 (1.6%) 2 (2.4%) 1 (1.0%) NS
Data is presented as the number of patients (percentage) or as mean ± SD; a p value refers to the comparison of values between patients with and
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vs 0.32 ± 1.35 ng/mL; p = NS) assay. Troponin levels deter-
mined at presentation in subgroups of patients categorised to
the three diagnostic groups, i.e. AMI, UA, and non-ACS are
presented in Figure 1 for both sensitive (panel A) and stan-
dard (panel B) troponin assays.
Diagnostic accuracy of the studied troponin assays
The ROC analysis showed greater AUC for the sensitive tro-
ponin assay compared to the standard troponin assay (AUC
0.916, 95% CI 0.866–0.951 vs AUC 0.863, 95% CI 0.806–
–0.909, respectively; p = 0.02) (Fig. 2). At the cut-off point at
the 99th percentile of the URL specific to each of the two
troponin tests sensitivity, specificity, PPV and NPV for AMI
diagnosis amounted to 87%, 88%, 86%, and 89% respective-
ly for sensitive assay and 82%, 81%, 78%, 85% respectively
for the standard assay (Table 2). Diagnostic parameters of the
two analysed troponin assays for the cut-off points at 99th
percentile URL and also at LOD and concentration at which
the assay reaches 10% CV are all shown in Table 2.
The ROC analysis of the diagnostic performance of sen-
sitive troponin assay in a single reading at admission yielded
similar results across subpopulations of patients with STEMI
(AUC 0.906, 95% CI 0.847–0.948) and NSTEMI (AUC 0.926,
95% CI 0.871–0.963), older (≥ 65 years) (AUC 0.910, 95%
CI 0.833–0.959) and younger (< 65 years) (AUC 0.918, 95%
CI 0.842–0.965) patients, and also in men (AUC 0.895, 95%
CI 0.826–0.944) and women (AUC 0.949, 95% CI 0.866–
Figure 1. Cardiac troponin I levels on admission of patients with chest pain determined by the two studied troponin assays.
Troponin levels at presentation of patients with chest pain admitted to the Institute of Cardiology are demonstrated as multiples
of the 99th percentile specific to each of the two tests. The boxes represent interquartile ranges, the horizontal line in each box
represents the median (the absence of a horizontal line indicates a median > 10 times the 99th percentile); the whiskers represent
the minimum and maximum values with exclusion of outliers that were more than 1.5 times of interquartile range. Multiples of
the 99th percentile greater than 10 are not shown; AMI — acute myocardial infarction; non-ACS — non-acute coronary syndrome;
UA — unstable angina; URL — upper reference limit
Figure 2. Receiver-operating characteristic curves (ROC)
depicting diagnostic performance of the studied troponin assays
in the diagnosis of acute myocardial infarction in a single
reading at admission. The continuous green line represents
diagnostic performance of the standard troponin I, and the
dashed green line represents diagnostic performance of the
sensitive troponin I. The figure incorporates areas under the
curve (AUC) together with 95% confidence intervals (CI) for
both assays and the p value for the difference between them
www.kardiologiapolska.pl
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–0.988). The percentage of patients with positive admission
troponin test readings across subgroups of patients with final
diagnoses of STEMI, NSTEMI, UA, and non-ACS is presented
in Figure 3.
In patients in whom AMI was excluded but who had
troponin elevation above the 99th percentile as determined
by standard assay at admission (n = 19, 13 [68%] male) the
excessive troponin release was attributable to decompensa-
ted heart failure (n = 1), cardiac arrhythmia (n = 4), myo-
carditis (n = 2), acute pulmonary embolism (n = 3), and
dissecting aneurysm of the ascending aorta (n = 1), and car-
diac contusion in an accident (n = 1); in seven patients, no
apparent cause of troponin elevation was evidenced. With
regard to the sensitive assay, in patients in whom AMI was
excluded but who had troponin elevation above the 99th
percentile as determined by sensitive assay at admission
(n = 12, 8 [67%] male), the excessive troponin release was
attributable to decompensated heart failure (n = 2), cardiac
arrhythmia (n = 4), myocarditis (n = 2), acute pulmonary
embolism (n = 2), and dissecting aneurysm of the ascen-
ding aorta (n = 1); in one patient no apparent cause of tro-
ponin elevation was evidenced.
DISCUSSION
Main study findings
The results of the current analysis show that a sensitive tropo-
nin assay compared to a standard troponin test presents su-
perior diagnostic performance in the diagnosis of AMI in a sin-
gle reading at admission. The superior diagnostic performan-
ce was evidenced by greater area under the ROC curve for
the sensitive assay and pertained with regard to both sensiti-
vity and specificity at the 99th percentile URL cut-off point.
The diagnostic accuracy of the sensitive assay proved to be
consistent among subgroups of patients with STEMI and NSTE-
MI, men and women, as well as older and younger patients.
Troponin assays and AMI guidelines
International guidelines on the New Definition of Myocardial
Infarction state that to make the diagnosis of AMI a rise and/or
fall of cardiac biomarkers of necrosis (preferably troponin) with
at least one value above the 99th percentile of URL should be
detected [11]. Troponin elevation is to be interpreted in the
clinical settings of the ongoing myocardial ischaemia.
This renders troponin a key element in the work-up of
patients with suspected AMI, especially with regard to NSTE-
MI. From the clinical standpoint, the treatment of STEMI sho-
uld be initiated based on clinical presentation and ECG ab-
normalities even if troponins have not yet been released into
circulation in sufficiently high quantities [4, 7]. The guidelines
also specify that troponin assays be characterised by preci-
sion (CV) at the 99th percentile URL equal to or less than 10%.
This requirement could not have been fulfilled in the past
due to technical shortcomings of contemporary tests. Impre-
cision greater than 10% may lead to both false positive and
Table 2. Diagnostic parameters of the two studied troponin I assays in a single reading at admission of patients with chest pain
Sensitivity Specificity PPV NPV
Sensitive troponin I assay
LOD (0.01 ng/mL) 94% 77% 77% 94%
99th percentile (0.028 ng/mL) 87% 88% 86% 89%
10% CV (0.032 ng/mL) 86% 89% 87% 88%
Standard troponin I assay
LOD (0.04 ng/mL) 89% 67% 69% 88%
99th percentile (0.07 ng/mL) 82% 81% 78% 85%
10% CV (0.14 ng/mL) 74% 88% 84% 80%
CV — coefficient of variation; LOD — lower limit of detection; NPV — negative predictive value; PPV — positive predictive value
Figure 3. Column chart presenting percentage of patients with
positive admission troponin test readings across subgroups of
patients with final diagnosis of ST elevation myocardial
infarction (STEMI), non-ST elevation myocardial infarction
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false negative results, especially in patients with blood tropo-
nin levels close to the 99th percentile URL. The new genera-
tion, sensitive assays are capable of detecting lower concen-
trations of cardiac troponins with increased precision at the
99th percentile of URL [10, 12]. Sensitive troponin assays have
been designed to detect myocardial necrosis earlier from its
onset with sufficiently high diagnostic precision.
The sensitive troponin assay
The sensitive assay used in the current study has imprecision
at the 99th percentile of URL equal to 15%, which is close to
the recommended level of 10% and outperforms the refe-
rence test (CV 15–22%). It also detects much lower levels of
troponin, although precise comparisons of troponin levels
obtained with various tests is precluded by their lack of stan-
dardisation. Indeed, in our study, improved analytical para-
meters of the sensitive assay translated into improved clinical
diagnostic performance.
Sensitive tests are characterised by lower troponin con-
centration at the 99th percentile URL and are capable of de-
tecting very low levels of troponins, often also in patients with
stable coronary artery disease or even apparently healthy in-
dividuals [10, 14]. This is why some authors argue that the
introduction of sensitive assays to daily clinical practice may
increase the frequency of NSTEMI diagnosis due to a decre-
ase in LOD and 99th percentile URL [15, 16]. Although it may
hold true for other tests or clinical circumstances our data
proves otherwise. As determined at admission, the sensitive
assay showed fewer false positive results. So not only was
specificity retained but it actually improved with the sensitive
test. This fact most probably results from greater CV of the
sensitive test compared to standard assay at low blood tropo-
nin concentrations (i.e. close to the 99th percentile). By defi-
nition, in lower ranges of protein concentration a standard
test will more often show false positive (as well as false nega-
tive) results only due to its insufficient laboratory precision.
In support of this assertion, out of 12 false positive results
of the sensitive test all but one (8.3%) had a cause of troponin
elevation attributable to specific causes other than AMI, whe-
reas in seven out of 19 (36.8%) false positive standard test
results, no apparent attributable cause was found. It may be
speculated that in patients in whom no apparent attributable
cause of troponin elevation was found, the cause was the
laboratory imprecision of the assay.
It has to be stressed that the sensitive tests do not merely
shift the 99th percentile to lower levels but rather re-establish it
based on improved lower limit of detection and coefficient of
variation (less imprecision). Importantly, the presence of myo-
cardial injury, i.e. troponin elevation due to causes other than
acute coronary ischaemia, will still require careful clinical judg-
ment to be distinguished from AMI [17–19]. Lack of a clinical
tool that is capable of distinguishing myocardial injury from
myocardial necrosis with 100% sensitivity and specificity is a li-
mitation of the current study and of other clinical research in
this area. It also constitutes a challenge for contemporary acu-
te cardiac care, especially in the case of NSTEMI. The greater
prevalence of myocardial injury among men caused a slight
difference between AUC for men and women in our cohort.
It is worth noting that the scope of troponin concentra-
tions below the 99th percentile of URL in patients without
AMI has been shown to portend strong prognostic informa-
tion regarding cardiovascular and overall morbidity and mor-
tality [14, 20–23]. Thus, sensitive troponin assays may open
a whole new chapter in preventive medicine and may bro-
aden our diagnostic and prognostic arsenal.
Perspective
Although our report, as well as others dealing with this sub-
ject suggest that sensitive assays may improve early diagnosis
of AMI [24–26], a few issues remain unresolved. First, there is
no data demonstrating whether introduction of the new ge-
neration assays would shorten the time from symptoms on-
set to treatment initiation and ultimately improve patients’
outcomes. Second, studies with serial troponin testing using
sensitive assays need to be performed. It has been sugge-
sted that sensitive tests may reliably exclude ongoing my-
ocardial necrosis with serial testing performed at three-ho-
urly instead of six-hourly intervals [27]. If this is proved, it
may bring some improvement to healthcare in general and
especially to Emergency Departments in terms of cost-savings
and overcrowding [8].
CONCLUSIONS
The results of the current analysis indicate that a sensitive tro-
ponin assay determined at admission compared to a stan-
dard troponin test is characterised by superior diagnostic per-
formance with improved sensitivity and specificity in ruling
AMI in or out. The diagnostic accuracy of the sensitive assay
proved to be consistent among subgroups of patients with
STEMI and NSTEMI, men and women, older and younger
patients.
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Wyższa wartość diagnostyczna czułego testu na
troponinę w porównaniu z testem standardowym
w diagnostyce ostrego zawału serca
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S t r e s z c z e n i e
Wstęp: Wczesne rozpoznanie ostrego zawału serca (AMI) warunkuje wdrożenie skutecznej terapii. Troponiny (Tn) sercowe
pełnią zasadniczą rolę w postępowaniu diagnostycznym. Jedną z istotniejszych wad tego markera jest opóźnienie czasowe
między początkiem martwicy miokardium a wykrywalnym wzrostem stężenia Tn w surowicy krwi. Postęp technologiczny
umożliwił w ostatnim czasie stworzenie tzw. czułych testów na Tn wykrywających znacznie niższe niż dotychczas stężenia
tego białka w surowicy krwi przy zachowaniu wysokiej precyzji diagnostycznej. Wartość diagnostyczna czułych testów w co-
dziennej praktyce klinicznej nie jest jednak wystarczająco dobrze udokumentowana.
Cel: Celem niniejszej pracy była ocena wartości diagnostycznej pierwszego oznaczenia stężenia Tn za pomocą czułego testu
w porównaniu z testem standardowym w diagnostyce AMI.
Metody: Do badania włączono kolejnych 187 pacjentów przyjętych do Instytutu Kardiologii z bólem w klatce piersiowej,
u których lekarz prowadzący podejrzewał ostry zespół wieńcowy (OZW) i zlecił oznaczenie stężenia Tn w surowicy krwi.
Badanie miało charakter obserwacyjny. Wszystkie kliniczne decyzje dotyczące diagnostyki i postępowania terapeutycznego
pozostawiono lekarzowi prowadzącemu. Testem referencyjnym (standardowym) był test Dimension Flex Troponin I (Sie-
mens Healthcare Diagnostics, Inc.). Dodatkowo z pierwszej próbki krwi pobranej w celu oznaczenia Tn standardowej ozna-
czono stężenie Tn czułym testem Architect Stat Troponin I (Abbott Diagnostics). Lekarz prowadzący nie miał wglądu w wynik
stężenia Tn oznaczonej czułym testem. Ostateczną diagnozę stawiało 2 niezależnych kardiologów na podstawie dostępnych
danych klinicznych i wyników badań dodatkowych uwzględniających wartości Tn oznaczonych testem standardowym. Roz-
poznanie zostało przyporządkowane do jednej z trzech kategorii: (1) AMI, (2) niestabilna choroba wieńcowa, (3) ból w klat-
ce piersiowej o etiologii innej niż OZW. Diagnozę AMI oparto na standardowych kryteriach (the Universal Definition of
Myocardial Infarction). Niestabilną chorobę wieńcową rozpoznano u pacjentów, którzy zgłaszali typowy ból wieńcowy spo-
czynkowy lub jego nasilenie w ostatnim czasie bez wzrostu stężenia Tn we krwi, i którzy mieli udokumentowaną obecnie lub
uprzednio chorobę wieńcową na podstawie badania koronarograficznego lub za pomocą prób obciążeniowych.
Wyniki: W analizowanej grupie obejmującej 187 pacjentów 63,6% (n = 119) stanowili mężczyźni, średni wiek wyniósł 64,3 ±
± 13,9 roku. Ostateczne diagnozę AMI postawiono u 84 (44,9%) pacjentów, u 43 (23%) rozpoznano zawał z uniesieniem
odcinka ST (STEMI), a u 41 (21,9%) zawał bez uniesienia odcinka ST (NSTEMI). Niestabilną chorobę wieńcową stwierdzono
u 11 (5,9%) osób, a ból w klatce piersiowej o etiologii innej niż OZW u pozostałych 92 (49,2%) pacjentów. Analiza ROC dla
stężenia Tn w surowicy krwi w pojedynczym oznaczeniu przy przyjęciu w diagnostyce AMI wykazała istotnie większe pole pod
krzywą (AUC) dla testu czułego w porównaniu z testem standardowym (odpowiednio AUC 0,916; 95% CI 0,866–0,951 v. AUC
0,863; 95% CI 0,806–0,909; p = 0,02). Dla punktu odcięcia równego 99-percentylowi górnej granicy referencji stężenia Tn
w zdrowej populacji dorosłych osób czułość, swoistość, dodatnia i ujemna wartość predykcyjna wyniosły odpowiednio 87%,
88%, 86% i 89% dla testu czułego oraz 82%, 81%, 78% i 85% dla testu standardowego; AUC dla czułego testu na Tn było
podobne w populacji pacjentów ze STEMI i NSTEMI, osób starszych (≥ 65. rż.) i młodszych (< 65. rż.) oraz u mężczyzn
i kobiet. W przypadku wyników fałszywie dodatnich dla testu standardowego (n = 19) oraz dla testu czułego (n = 12) odpo-
wiednio w 12 (63,2%) i w 11 (97,1%) przypadkach występowała klinicznie jawna przyczyna wzrostu Tn inna niż AMI.
Wnioski: Czuły test wykazuje wyższą wartość diagnostyczną w porównaniu z testem standardowym w diagnostyce AMI u cho-
rych z bólem w klatce piersiowej w pojedynczym oznaczeniu przy przyjęciu. Dla punktu odcięcia równego 99. percentlowi
górnej granicy referencyjnej stężenia Tn w zdrowej populacji test czuły wykazuje zarówno wyższą czułość, jak i zwiększoną
swoistość. Wprowadzenie testu czułego do praktyki klinicznej może usprawnić wczesne rozpoznanie i/lub wykluczenie AMI.
Słowa kluczowe: czuły test na troponinę sercową, ostry zawał serca, diagnostyka laboratoryjna
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